Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

News Daily News

FDA Grants Stroke Prevention Indication to Ticagrelor

Shelley Wood

November 06, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

Todd Neale

May 04, 2017

Advertisement

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

FDA Grants Stroke Prevention Indication to Ticagrelor

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content